Product Description
AXT-1003 is a small molecule epigenetic inhibitor developed for treatment of cancer. Axter has signed the Licensing Agreement with Novartis and acquired the license for AXT-1003’s global development and commercialization. Currently, there are comprehensive ongoing preclinical activities in both China and US. (Sourced from: https://www.axtertx.com/jsycp)
Mechanisms of Action: EZH2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: Axter
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| AXT1003-1102 | P1 |
Recruiting |
Lymphoma, Non-Hodgkin |
2027-03-01 |
23% |
2024-09-28 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| CTR20242194 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|